Compounds with Potential Use in Development of Medications for the Treatment of Multidrug Resistant HIV-1

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	2015-GHOS-67161
Categories	Chemistry and Chemical Analysis Pharmaceuticals
Keywords	Antivirals Drug Development Drug Resistance Enzymes HIV/AIDS Inhibitors Pharmaceuticals Pharmacology Protease Inhibitors
Public Abstract	HIV/AIDS is one of the top deadly diseases worldwide that is still common despite progress in healthcare. Human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS), which is a complex disease that includes gradual destruction of the immune system. Many current therapies that are available for the management of the disease are limited by their duration of action, side effect profile and toxicity, and their extensive pill burden. Hence, there is a need to find newer therapies for HIV/AIDS. Researchers at Purdue University have developed a series of non-peptide HIV-1 protease inhibitors that incorporate a basic amine function in the inhibitor structure. These compounds are novel and show enzyme inhibition and antiviral activity at subnanomolar levels. In addition, they have been shown to have potent activity against multidrug resistant HIV-1 strains and are expected to have improved metabolic stability and pharmacokinetic properties. These compounds have potential use in the pharmaceutical industry for the development of superior HIV medications and in healthcare for the treatment of HIV/AIDS. Advantages: -HIV-1 protease inhibitor -Potent activity against resistant strains -Improved stability and pharmacokinetics Potential Applications: -Pharmaceutical industry -Drug development -Medical/Healthcare -Treatment of HIV/AIDS
People	Ghosh, Arun K (Project leader) Martyr, Cuthbert D. Mitsuya, Hiroaki
Intellectual Property	Application Date Aug 17, 2016 Type NATL-Patent Country of Filing European Patent Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing United Kingdom Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing Switzerland Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing Germany Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing France Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing Denmark Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing Belgium Patent Number 3337567 Issue Date Oct 6, 2021 Application Date (None) Type EP-Patent Country of Filing Ireland Patent Number 3337567 Issue Date Oct 6, 2021 Application Date Feb 17, 2018 Type NATL-Patent Country of Filing United States Patent Number 10,472,372 Issue Date Nov 12, 2019 Application Date Oct 10, 2019 Type CON-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Aug 17, 2016 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Aug 17, 2016 Type NATL-Patent Country of Filing Japan Patent Number (None) Issue Date (None) Application Date Aug 17, 2016 Type DIV-Patent Country of Filing Japan Patent Number (None) Issue Date (None) Application Date Aug 17, 2015 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org